Four AIM strugglers with recovery potential
Our award-winning AIM expert discusses how some of 2019’s worst performers could bounce back this year.
Read More
Silence Therapeutics PLC – Interim results
Silence Therapeutics, PLC (LON: SLN), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces its unaudited interim results for the half year to 30 June 2019.
Silence Therapeutics PLC – Board Update
LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that further to the announcements on 18 July 2019 detailing the Company’s collaboration with and equity investment by Mallinckrodt plc (NYSE: MNK), Steven Romano, MD, has today joined the Board of Silence as a Non-Executive Director.
Silence Therapeutics PLC – Collaboration with Genomics England
Silence Therapeutics, PLC (LON: SLN)a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has entered into a collaboration with Genomics England Limited for the investigation of novel targets involved in human disease.
Silence Therapeutics PLC – Silence Therapeutics Announces Board Changes
Silence Therapeutics, PLC (LON: SLN) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that Iain Ross has joined as a Non-Executive Director and Chairman of the Board of Directors with immediate effect. Silence also announces that James Ede-Golightly has joined as a Non-Executive Director and that Stephen Parker is stepping down as a Non-Executive Director, both with immediate effect.
Silence Therapeutics PLC – Appointment of Chief Financial Officer
Silence Therapeutics, PLC (LON: SLN) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce the appointment of Rob Quinn as full time Chief Financial Officer, effective immediately.
Silence Therapeutics PLC – Silence Therapeutics appoints Head of R&D and CMO
Silence Therapeutics, PLC (LON: SLN) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce the appointment of Giles Campion, MD as Head of R&D and Chief Medical Officer, effective 1 June 2019.
Silence Therapeutics PLC – 2018 Preliminary Results
Silence Therapeutics, PLC (LON: SLN) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces its unaudited preliminary results for the year ended 31 December 2018.
Silence Therapeutics PLC – New divisional patent and injunction application
Silence Therapeutics plc, (LON:SLN) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, confirms the receipt of a notice of intention to grant for a new European divisional patent, EP 3 222 724B, and further said that it has commenced a new cross-border interim injunction application in the Netherlands against Alnylam’s Onpattro™ (patisiran).
Silence Therapeutics PLC – Interim results
Silence Therapeutics plc, AIM:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases, announces its unaudited interim results for the half year to 30 June 2018.